Investigating how early life challenges affect drug use risks in adolescents
A Neuroecological Approach to Examining the Effects of Early Life Adversity on Adolescent Drug Use Vulnerabilities Using the ABCD Dataset
This study looks at how tough experiences in childhood might affect drug use in teens aged 12 to 20, and it aims to find out how family, friends, school, and community play a role in this, so we can better understand why some young people might be more at risk for using drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10930164 on NIH RePORTER |
What this research studies
This research examines the impact of early life adversity on the risk of drug use among adolescents aged 12 to 20. It utilizes the ABCD dataset to explore how various family, peer, school, and community factors influence neurocognitive development and drug use behaviors. By focusing on the interplay between emotional regulation and cognitive control, the study aims to identify neural biomarkers that could predict vulnerabilities to drug use. The findings could help in understanding the complex dynamics that contribute to adolescent drug misuse.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents aged 12 to 20 who have experienced early life adversity.
Not a fit: Patients who have not experienced early life adversity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prevention strategies and interventions for adolescents at risk of drug use due to early life challenges.
How similar studies have performed: Previous research has shown promising results in understanding the links between early life adversity and adolescent behavior, suggesting that this approach could yield valuable insights.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Oshri, Assaf — University of Georgia
- Study coordinator: Oshri, Assaf
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.